Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer

This publication has 14 references indexed in Scilit:

• Dual‐colour chromogenic in situ hybridization for testing of HER‐2 oncogene amplification in archival breast tumours
  The Journal of Pathology, 2006
• Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
  Laboratory Investigation, 2006
• Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
  Laboratory Investigation, 2005
• Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer
  Journal of Molecular Histology, 2004
• Interlaboratory Comparison ofHER-2Oncogene Amplification as Detected by Chromogenic and Fluorescencein situHybridization
  Clinical Cancer Research, 2004
• Best Practice No 176: Updated recommendations for HER2 testing in the UK
  Journal of Clinical Pathology, 2004
• HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
  Journal of Clinical Oncology, 2004
• Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
  APMIS, 2003
• Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma
  Laboratory Investigation, 2002
• Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
  Journal of Clinical Oncology, 2000